GlobeNewsWire
08 Dec 2025, 15:30 UTC · 40w ago
Verdict
Headline takes no side. We score 4151 +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Ziftomenib in combination with venetoclax and azacitidine showed an 86% composite complete remission rate in newly diagnosed NPM1-m AML patients.
More positive than 98% of claims this week
The triplet combination demonstrated a favorable safety profile, with ziftomenib not increasing toxicity beyond that of venetoclax/azacitidine alone.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 92% of claims this week
Relapsed/refractory NPM1-m AML patients showed an 83% overall response rate if they were venetoclax-naïve, and 65% ORR overall.
More positive than 85% of claims this week
Company-sponsored registrational trials of ziftomenib in front-line AML are currently ongoing for both chemotherapy-eligible and ineligible patients.
More positive than 77% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
As a partner in the trial, the company benefits from the encouraging antileukemic activity and safety data reported for KOMZIFTI.
More positive than 88% of ticker scores this week
The company reported positive clinical trial data demonstrating high response rates and a favorable safety profile for its drug KOMZIFTI.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Benzinga
11h ago
—
No price for 4151 right now — the quote feed didn't answer.
4151 chart →
